

ZOGENIX



Zogenix to Participate in the Leerink Partners 4th Annual Rare Disease Roundtable

September 23, 2015

SAN DIEGO, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Leerink Partners 4th Annual Rare Disease Roundtable in New York, NY, on September 30, 2015.

Leerink Partners 4th Annual Rare Disease Roundtable

Date: Wednesday, September 30, 2015

Time: 9:40 am Eastern Time / 6:40 am Pacific Time

Location: New York, NY - Le Parker Meridien, Tansa Room

The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to help them return to normal daily functioning.

For more information, visit www.zogenix.com.

CONTACT: Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com

Zogenix, Inc.